Epilepsy: Antiseizure Drug Interactions with Cannabidiol

Research into the use of the marijuana derivative cannabidiol (CBD) is just beginning. In an abstract presented at the American Epilepsy Society 69th Annual Meeting in Philadelphia, PA, a team described their ongoing work. Misty Smith, PhD, a research assistant professor at the University of Utah in Salt Lake City, UT, and colleagues are looking at how cannabidiol interacts with traditional anti-seizure drugs.
The current project compares the relative anticonvulsant efficacy of CBD with five mechanistically-different ASDs (i.e., carbamazepine (CBZ), valproate (VPA), levetiracetam (LEV), clobazam (CBM), and lacosamide (LAC)). The studies test the hypothesis that CBD will have supra-additive (synergistic) effects when administered in combination with mechanistically-different, yet compatible, ASDs without enhancing adverse events.
So far, they have identified “significant synergistic interaction” with LEV at the 1:1 fixed ratio (FR) combination (P0.01), whereas significant antagonistic interactions have been identified with CBM at the

... read more at: http://www.hcplive.com/conference-coverage/aes-2015/epilepsy--antiseizure-drug-interactions-with-cannabidiol